1 / 21

Future treatment of HCV with Host Targeting Antivirals

Future treatment of HCV with Host Targeting Antivirals. Francesco Negro University Hospitals, Geneva, Switzerland. Host-Targeting Antivirals (HTA) vs. Direct Acting Antivirals (DAA). PRO’s. CON’s. Risk of toxicity due to interference with cellular functions.

tejana
Download Presentation

Future treatment of HCV with Host Targeting Antivirals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Future treatment of HCVwith Host Targeting Antivirals Francesco Negro University Hospitals, Geneva, Switzerland

  2. Host-Targeting Antivirals (HTA)vs. Direct Acting Antivirals (DAA) PRO’s CON’s • Risk of toxicity due to interference with cellular functions • Less or no risk of selecting drug resistance • Pan-genotypic activity

  3. Host factors as target for anti-HCV therapy Adapted from VON HAHN et al, 2011; HERKER et al, 2010; SAINZ et al, 2012 TROTARD et al, 2009; LUPBERGER et al, 2011

  4. Alisporivir (DEBIO-025), a cyclophilin inhibitor without immunosuppressive effects DEBIO-025 CsA Cyclophilin binding domain Calcineurin binding domain

  5. Alisporivir binds to cyclophilin but not to calcineurin Alisporivir-Cyp complexdoes NOT bind to CN leaving immune response intact CyP Cyclosporin A-cyclophilin complex binds calcineurin CyP alisporivir CsA CN CN CN NF-ATc dephosphorylation is blocked P P Activation of immune response NF-ATc NF-ATc NF-ATc

  6. CYCLOPHILINS ARE CHAPERONES PENG et al, 2005; RYFFEL et al, 1991; COLGAN, et al. 2004 • Cyclophilins have diverse cellular functions • Ubiquitous proteins • Expressed in various tissues(liver, muscle, CNS) • >7 subtypes reported in humans • Detected in cytosol, nucleus, ER, mitochondria (depending on subtype) • Peptidyl prolyl isomerase (PPIase) activity • Catalyzes isomerization of peptidic bonds from trans to cis to facilitate the de novo protein unfolding • HCV exploits the PPIase activity ofCypA for its own replication

  7. Cyclophilin A (CyPA) is the main cyclophilin involved in HCV replication Yang F, et al. J Virol 2008;82:5269–5278; Chatterji U, et al. J Biol Chem 2009;284:16998–17005 Kaul A, et al. PLoS Pathog 2009;5:e1000546

  8. Additional effects of cyclophilin inhibition in HCV infection • Restoration of mitochondrial function QUARATO et al, Hepatology 2011 • Reduction of autophagy, thus limiting the inhibitory effect of autophagy on innate immune response CARREIRA et al, Autophagy 2010

  9. Alisporivir FLISIAK et al, Hepatology 2009; FERNANDEZ et al. Hepatology 2007; GOTTO et al, Cancer Sci 2009 CRABBE et al Expert Opin Investig Drugs 2009; WIEDERMANN et al, Antimicrob Agents Chemother 2010 FLISIAK et al, EASL 2011; CHATTERJI et al, J Hepatol 2010; COLMONT et al, PLoS One 2010 Pan-genotype antiviral activity • As a monotherapy or added to SOC, G1-4 High resistance barrier • Mutations associated with resistance to Cyp inhibitors can be selected in vitro within NS5A (a substrate of PPIase activity of CypA) but appear very slowly (28 passages, 4-6 months) • The D320E (domain III of NS5A) mutation is associated with resistance to alisporivir (cross-resistance to CsA and alisporivir) but is not sufficient to lead to breakthrough in patients • Resistance is low-level (<5-fold) and involves reduced binding to CyPA

  10. Alisporivir monotherapy or in combination with SOC[4 weeks, treatment-naive, HCV genotypes 1 and 4] FLISIAK et al, Hepatology 2009;49:1460–1468

  11. Alisporivir monotherapy or in combination with SOC[4 weeks, treatment-naive, HCV genotypes 2 and 3] FLISIAK et al, Hepatology 2009;49:1460–1468

  12. Dreaming about an IFN-a-free world...

  13. The ESSENTIAL Study (205 Study)Multicenter (EU), 48 weeks, treatment-naive, HCV-1, phase IIb RCTITT population (n=288) PEG-IFN-a/RBV (n=73) Placebo + PEG-IFN-a /RBV 48 weeks FU 600 mg BID first week then 600mg QD Alisporivir48 (n=72) Alisporivir + PEG-IFN-a /RBV 48 weeks FU RVR Alisporivir-RGT (n=71) Alisporivir + PEG-IFN-a /RBV 24-48 weeks FU non-RVR Alisporivir24 (n=72) Alisporivir + PEG-IFN-a /RBV 24 weeks FU 0 24 48 72 FLISIAK et al, EASL 2011

  14. The ESSENTIAL Study – SVRITT population (n=288) P=0.008 39/73 49/71 34/72 54/72 FLISIAK et al, EASL 2011

  15. Alisporivir + PEG-IFN-a/RBV is superior to PEG-IFN-a/RBV: RVR was ~3-fold higher in all alisporivir-containing arms SVR increased from 55% to 76% in the 48-week triple regimen Improvement of SVR was independent of IL28B genotype Triple regimen was well tolerated (transient, reversible hyperbilirubinemia in ~1/3 of patients, without cholestasis or hepatotoxicity) The ESSENTIAL Study (205 Study)ITT population (n=288) FLISIAK et al, EASL 2011

  16. Alisporivir disposal and risk of DDIs DEB025 is mainly metabolised through cytochrome P450 3A4 DEB025 is an inhibitor of P-gp, BSEP, MRP2 (leading to hyperbilirubinemia), NTCP, OATP1B1 and OATP1B3

  17. Alisporivir– Ongoing phase III program

  18. miRNA-122 is essential to HCV replication Miravirsen (Santaris) is a small LNA modified phosphorothioate anti-sense oligonucleotide targeting (and blocking) miR-122 JOPLIN et al, Science 2005; JANSSEN et al, AASLD 2011

  19. Preclinical and phase 1 data on Miravirsen • Miravirsen inhibits HCV in vitro (EC50 0.67 mm) • No resistance-conferring mutations in the miR-122 seed regions (conserved among HCV genotypes) • In healthy volunteers, safe and well tolerated, with no dose limiting toxicity LANFORD et al, Science 2010; ELMEN et al, Nature 2008

  20. Proof-of-concept study of Miravirsen (oligonucleotide targeting miR-122) in treatment-naïve HCV-1 JANSSEN et al, AASLD 2011

  21. Mean HCV RNA Log changes during Miravirsen Prolonged dose-dependent antiviral activity well beyond the end of therapy, consistent with 30 day terminal half-life No evidence of drug resistance JANSSEN et al, AASLD 2011

More Related